✦ LIBER ✦

Natalizumab promising for moderately to severely active Crohn's disease

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ustekinumab for Moderate-to-Severe Crohn

✍ Gupta Konijeti, Gauree; Chan, Andrew T. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 154 KB

Natalizumab for moderate to severe Crohn

✍ S.V. Kane; S. Horst; W.J. Sandborn; B. Becker; B. Neis; M. Moscandrew; K.A. Hans 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 726 KB

Oral butyrate for mildly to moderately a

✍ A. DI SABATINO; R. MORERA; R. CICCOCIOPPO; P. CAZZOLA; S. GOTTI; F. P. TINOZZI; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

649 A Randomized Placebo-Controlled Tria

✍ Stephen B. Hanauer; William J. Sandborn; Bruce E. Sands; Paul J. Rutgeerts; Remo 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 76 KB

W1095 Natalizumab Use in Clinical Practi

✍ Moscandrew, Maria E.; Becker, Brenda D.; Sandborn, William J.; Pardi, Darrell S. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 117 KB

922 Adalimumab Maintains Long-Term Remis

✍ Remo Panaccione; Jean-Frédéric Colombel; William J. Sandborn; Paul Rutgeerts; Ge 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 173 KB